Geode Capital Management LLC increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 12.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 883,786 shares of the biopharmaceutical company’s stock after buying an additional 98,114 shares during the period. Geode Capital Management LLC’s holdings in Celldex Therapeutics were worth $3,190,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. American International Group Inc. raised its position in shares of Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 3,880 shares during the last quarter. TSP Capital Management Group LLC raised its position in shares of Celldex Therapeutics by 20.0% in the first quarter. TSP Capital Management Group LLC now owns 1,063,248 shares of the biopharmaceutical company’s stock valued at $3,838,000 after buying an additional 176,850 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of Celldex Therapeutics by 26.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 6,000 shares during the last quarter. State of Wisconsin Investment Board raised its position in shares of Celldex Therapeutics by 206.3% in the first quarter. State of Wisconsin Investment Board now owns 750,000 shares of the biopharmaceutical company’s stock valued at $2,708,000 after buying an additional 505,138 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in shares of Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 1,409 shares during the last quarter. Institutional investors and hedge funds own 63.88% of the company’s stock.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded down 0.86% during mid-day trading on Monday, reaching $2.31. 204,247 shares of the company were exchanged. Celldex Therapeutics, Inc. has a 12 month low of $2.20 and a 12 month high of $5.02. The company’s market cap is $296.47 million. The stock’s 50-day moving average is $2.44 and its 200-day moving average is $2.97.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. During the same period last year, the business earned ($0.32) EPS. The firm’s revenue was up 175.5% compared to the same quarter last year. Equities analysts expect that Celldex Therapeutics, Inc. will post ($1.04) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Celldex Therapeutics, Inc. (CLDX) Stake Raised by Geode Capital Management LLC” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2017/08/21/celldex-therapeutics-inc-cldx-stake-raised-by-geode-capital-management-llc.html.

Several research analysts have recently weighed in on the stock. Jefferies Group LLC reiterated a “hold” rating and set a $3.50 price objective (down from $4.00) on shares of Celldex Therapeutics in a report on Thursday, May 11th. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a report on Wednesday, May 31st. ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, June 3rd. HC Wainwright set a $10.00 price objective on shares of Celldex Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Aegis reiterated a “buy” rating on shares of Celldex Therapeutics in a report on Thursday, June 29th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.32.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.